Baird Maintains Outperform on Nevro, Lowers Price Target to $188
Baird analyst Mike Polark maintains Nevro (NYSE:NVRO) with a Outperform and lowers the price target from $200 to $188.
Nevro Announces Presentation Of SENZA-NSRBP Clinical Data At American Society Of Interventional Pain Physicians 23rd Annual Meeting Jun. 24-26
PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that data from the SENZA
Earnings Scheduled For May 5, 2021
Companies Reporting Before The Bell
• Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter.
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.
Stocks That Hit 52-Week Highs On Wednesday
During the morning session on Wednesday, 398 stocks hit new 52-week highs. Interesting Highlights: Alphabet (NASDAQ:GOOGL) was the largest company…